ABSTRACT
Purpose:To compare the response and toxic reaction of 3-weeks’ and weekly taxotere/cisplation treatment in non-small-cell lung cancer. Methods:Group A: Taxotere 75mg/m~2 IV d 1,cisplatin 25mg/m~2 d 1-3 q3-4w; Group B: Taxotere 60 mg IV d1, taxotere 40 mg IV d8,d15, cisplatin 25 mg/m~2 IV d 1,d 8,d 15 q3-4w. The clinical responses were assessed after two cycles. Toxicity was assessed every cycle. Results:There was no CR in the 71 cases . There were 14 PR, 13 SD in group A; there were 16 PR, 14 SD in group B. The overall response rates were 41.2% and 44.4% in group A and B. The rates of grade Ⅲ/Ⅳ neatropenia were 70.6% and 25% in group A and B. The major nonhematologic toxicity was weakness. The rates of weakness were 44.1% and 19.4% in group A and B. Conclusions:The response rates were similar between groups A and B. The occurrence of hematologic toxicity and weakness were lower in weekly treatment.
ABSTRACT
Background and purpose:The majority of patients with gastric cancer are in advanced stage with either extensive invasion of tumor into the adjacent organs,lymph nodes or distant metastases when diagnosed.As a new anticancer drug of Taxanes,docetaxel has shown considerable promise in advanced gastric cancer through clinical study in these years.We conducted a clinical trial to compare the response and toxic reaction of weekly and 3-weeks'docetaxel /cisplatin/5-Fu treatment in advanced gastric cancer.Methods:80 patients were deviede into two groups.Ggroup A:Docetaxel 25 mg/m2 iv d 1,8,15,cisplatin 25 mg/m2 iv d 1-3,5-FU 500 mg/m2 iv d 1-5 q4w.Group B:Docetaxel 75 mg/m2 iv d 1,cisplatin 25 mg/m2 iv d 1-3,5-FU 500 mg/m2 iv d 1-5 q3w;The clinical responses were assessed after two cycles.Toxicity was assessed every cycle.Results:There was 1 CR in 40 cases,16 with PR,14 with SD in group A;there was 1 CR in 40 cases,17 with PR,14 with SD in group B.The overall response rates were 42.4% and 45.0% in group A and B,respectively.Grade Ⅲ/Ⅳ neatropenia were 32.5% and 77.5% in group A and B.The major non-hematologic toxicity was weakness.Grade Ⅲ/Ⅳ weakness were 22.5% and 42.5% in group A and B.Conclusions:The response rates were similar between groups A and B.The occurrence of hematological toxicity and weakness were lower in weekly treatment group.